Merck & Co., Inc. with ticker code (MRK) now have 25 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $155.00 and $124.50 and has a mean share price target at $142.79. (at the time of writing). Now with the previous closing price of $127.30 this indicates there is a potential upside of 12.2%. The 50 day MA is $129.04 and the 200 day MA is $118.56. The market cap for the company is 326.66B. The stock price for the company is currently $128.97 USD
The potential market cap would be $366,404,402,389 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 143.3, revenue per share of $24.22 and a 10.26% return on assets.
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services for the prevention, treatment and control of disease in all major livestock and companion animal species.
